Cancer and Alzheimer’s disease are two of the most feared diagnoses in medicine, but they rarely strike the same person. For years, epidemiologists have noticed that people with cancer seem less likely to develop Alzheimer’s, and those with Alzheimer’s are less likely to get cancer, but nobody could explain why. A new study in mice suggests a surprising possibility: certain cancers may actually send a protective signal to the brain that helps clear away the toxic protein clumps linked to Alzheimer’s disease.
Alzheimer’s is characterised by sticky deposits of a protein called amyloid beta that build up between nerve cells in the brain. These clumps, or plaques, interfere with communication between nerve cells and trigger inflammation and damage that slowly erodes memory and thinking. In the new study, scientists implanted human lung, prostate and colon tumours under the skin of mice bred to develop Alzheimer‑like amyloid plaques.
Left alone, these animals reliably develop dense clumps of amyloid beta in their brains as they age, mirroring a key feature of the human disease. But when the mice carried tumours, their brains stopped accumulating the usual plaques. In some experiments, the animals’ memory also improved compared with Alzheimer‑model mice without tumours, suggesting that the change was not just visible under the microscope.
Read Full Article on TimesLIVE
[paywall]
The study slots into a growing body of research suggesting that the relationship between cancer and neurodegenerative diseases is more than a statistical quirk. Large population studies have reported that people with Alzheimer’s are significantly less likely to be diagnosed with cancer, and vice versa, even after accounting for age and other health factors The team traced this effect to a protein called cystatin‑C that was being pumped out by the tumours into the bloodstream. The new study suggests that, at least in mice, cystatin‑C released by tumours can cross the blood–brain barrier — the usually tight border that shields the brain from many substances in the circulation.
Once inside the brain, cystatin‑C appears to latch on to small clusters of amyloid beta and mark them for destruction by the brain’s resident immune cells, called microglia. These cells act as the brain’s clean‑up crew, constantly patrolling for debris and misfolded proteins. In Alzheimer’s, microglia seem to fall behind, allowing amyloid beta to accumulate and harden into plaques.
In the tumour‑bearing mice, cystatin‑C activated a sensor on microglia known as Trem2, effectively switching them into a more aggressive, plaque‑clearing state. At first glance, the idea that a cancer could “help” protect the brain from dementia sounds almost perverse. Yet biology often works through trade-offs, where a process that is harmful in one context can be beneficial in another.
In this case, the tumour’s secretion of cystatin‑C may be a side‑effect of its own biology that happens to have a useful consequence for the brain’s ability to handle misfolded proteins. It does not mean that having cancer is good, but it does reveal a pathway that scientists might be able to harness more safely. Large population studies have reported that people with Alzheimer’s are significantly less likely to be diagnosed with cancer, and vice versa, even after accounting for age and other health factors.
[/paywall]
